Posted by Michael Wonder on 10 Aug 2017
Patients getting faster access to cancer drugs as NICE approves three quarters of the Cancer Drugs Fund
10 August 2017 - Liver cancer drug, sorafenib has been approved for routine NHS use, marking three quarters of the way through the Cancer Drugs Fund without a negative decision.
NICE has recommended sorafenib, also known as Nexavar, made by Bayer to be routinely available for some patients on the NHS.
Sorafenib is one of the 24 drugs NICE was asked to appraise from the Cancer Drugs Fund (CDF), and all have been approved so far for routine NHS use.
Its positive recommendation means that NICE is three quarters of the way through the CDF with 18 drugs now approved.
